Zoledronic acid 4mg/vial with ampoule of 5ml water for reconstitution: injection.

Ind: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hyperealcaemia) in patients with advanced malignancies involving bone. Treatment of hyperealcaemia of malignancy (HCM).

C/I; S/E; Precaution; See above under the text. Dosage & admin: For prevention of skeletal- related events in patients with advanced malignancies involving bone, the recommended dose is 4mg given as a 15-minute i.v infusion every 3 to 4 weeks.

For treatment of HCM, the recommended dose is 4mg given as a single 15-minute i.v infusion. Patients who show complete response and relapse, or who are refractory to initial treatment may be retreated with zoledronic acid 8mg given as a single 15-minute i.v infusion. However, at least 1 week must elapse before retreatment to allow for a full response to the initial dose.

No dose adjustment is necessary in patients with mild to moderate renal impairment.

Drug inter: See above under the text.

4mg (5ml) vial x Fs pack: 26122.00 MRP